menu
    • menu
    [{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenikos B.V \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Undisclosed"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"CD3\/7||CD3\/CD7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenikos B.V \/ Xenikos B.V","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Xenikos B.V"}]

    Find Clinical Drug Pipeline Developments & Deals by Xenikos B.V

    Menu

    Xenikos B.V

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Veloxis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study E...

                            Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...

                            Product Name : T-Guard

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 28, 2022

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Veloxis Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Re...

                            Details : T-Guard (ricin toxin A conjugated mAB) is designed to safely and swiftly reset the body’s immune system in life-threatening T cell‒mediated conditions, including transplant-related rejection, acute solid-organ rejection, and severe autoimmune disease...

                            Product Name : T-Guard

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 27, 2022

                            Lead Product(s) : T-Guard,Dafsolimab Setaritox

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT...

                            Details : T-Guard is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 22, 2021

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

                            Details : T-Guard is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 16, 2019

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Blood and Marrow Transplant Clinical Trials Network | National Cancer Institute | National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenikos B.V

                            Netherlands arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD

                            Details : T-Guard is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 06, 2014

                            Lead Product(s) : T-Guard

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth